Applied Therapeutics (NASDAQ:APLT) Coverage Initiated by Analysts at Cowen
Cowen started coverage on shares of Applied Therapeutics (NASDAQ:APLT) in a research report sent to investors on Monday, BenzingaRatingsTable reports. The firm issued an outperform rating on the stock.
Several other equities research analysts also recently weighed in on APLT. UBS Group began coverage on shares of Applied Therapeutics in a research note on Monday. They issued a buy rating for the company. Robert W. Baird began coverage on shares of Applied Therapeutics in a research note on Monday. They issued an outperform rating and a $24.00 target price for the company.
Shares of APLT opened at $9.76 on Monday. Applied Therapeutics has a twelve month low of $7.95 and a twelve month high of $11.20.
Applied Therapeutics Company Profile
Applied Therapeutics, Inc, a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy.
Recommended Story: What does an outperform rating mean?
Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.